A number of strategies are currently under clinical trial in breast cancer patents using either alkylating agents (NCIC, 2001) or pseudosubstrates (Spiro et al, 1999) to deplete tumour ATase and hence increase tumour chemosensitivity. The gene discussed is PPAT; the disease is neoplasm.